Jenna Payesko

Of the 246 patients who underwent lung resections, 203 patients had a FEV1 less than 0.8.

Miners who have worked 10 or more years are at greater risk for developing black lung disease and progressive massive fibrosis.

Under Medicaid expansion, declines in ICU admission may mean that increased access to insurance has led to improvements in clinical outcomes.

Smokers who quit had lower disease risk than the group identified as stable, low-rate smokers.

A type of flavonoid found in dark-pigmented fruits like red grapes and blueberries may slow the lung function decline that occurs with aging.

Reducing use of opiates near the end of hospital stay, especially 24 hours prior to discharge, may reduce outpatient prescription of opioids.

Infants whose mothers were exposed to carbon monoxide in the second and third trimester were at highest risk for reduced lung function when they were tested at 1 month of age.

The hazard ratios for ozone measured at bone as a single pollutant showed statistically significant higher risks for development of asthma, allergic rhinitis and eczema.

The FDA will come to a conclusion on whether to approve Epidiolex in late June and if approved, this will be the first cannabis-based product to become FDA approved.

This is the first FDA-approved non-opioid treatment for the management of opioid withdrawal symptoms, providing a new option for patients to select treatment best suited to their needs.

The safety and efficacy of diacerein 1% ointment is being evaluated in the DELIVERS study.

The investigational new drug application allows the initiation of phase 1/2 clinical trial to assess the safety of BIVV003 in adults.

This is the first agent indicated for uninfected adolescents at risk of acquiring HIV.

The approval is backed by evidence from extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data and other clinical safety and effectiveness data.

The system is designed for the 3D visualization of bone detail in the lower extremities while the patient remains standing so the anatomy can be assessed while in load bearing positions.

Phase 2 clinical study suggests L1-79 has the potential to address an unmet medical need for the treatment of the core symptoms of autism spectrum disorder.

Actemra offers an alternative delivery option to physicians and parents of children 2 years or older to treat PJIA.

Approval provides pediatric epilepsy patients a treatment option to be administered at a therapeutic dose from day 1/

Oral amoxicillin and intravenous ertapenem kill commensal bacteria and increase risk for antibiotic resistance in Clostridium difficile.

The data may be helpful for clinicians in developing treatment courses for patients exhibiting withdrawal symptoms from short-acting opioids.

Employed patients who were also impaired on functional capacity measures, showed larger overall treatment response than unemployed patients regardless of functional capacity measure scores.

The technology includes enhanced features like a patient management system that increases the ease of use for physicians.

MDD and PTSD are significantly associated with military trauma and PTSD specifically, is at an increased with military sexual trauma among females.

History of psychiatric disorder, especially in fathers and brothers, is highly valuable information to identify women most at risk for postpartum psychiatric illness.

Patients with cannabis and cocaine use disorder have different impulsivity profiles, especially with relation to differences in attentional impulsiveness.

Results demonstrate potential to address a significant unmet for more than 30% of those suffering from treatment-resistant depression.

Firearm use in the not guilty by reason of insanity population is more closely related to substance use and personality disorder than psychotic or mood disorders.

The associated PTSD comorbidities represent a significant public health problem that’s concomitant with increased disease burden and mortality.

If FDA approved, it would be the first-in-class pharmacologic treatment for hyperbilirubinemia in newborns that contains a novel mechanism of action inhibiting bilirubin production at the source.

This is the first FDA-approved antidepressant for MDD to have data in US Prescribing Information showing a positive effect on processing speed.